352 related articles for article (PubMed ID: 33213897)
1. HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
O'Toole SA; Huang Y; Norris L; Power Foley M; Shireen R; McDonald S; Kamran W; Ibrahim N; Ward M; Thompson C; Murphy C; D'Arcy T; Farah N; Heron E; O'Leary JJ; Abu Saadeh F; Gleeson N
Gynecol Oncol; 2021 Feb; 160(2):514-519. PubMed ID: 33213897
[TBL] [Abstract][Full Text] [Related]
2. Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.
Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kinalski M; Terlikowski SJ
Adv Med Sci; 2016 Mar; 61(1):23-7. PubMed ID: 26344910
[TBL] [Abstract][Full Text] [Related]
3. The preoperative serum CA125 can predict the lymph node metastasis in endometrioid-type endometrial cancer.
Ünsal M; Kimyon Comert G; Karalok A; Basaran D; Turkmen O; Boyraz G; Tasci T; Koc S; Boran N; Tulunay G; Turan T
Ginekol Pol; 2018; 89(11):599-606. PubMed ID: 30508211
[TBL] [Abstract][Full Text] [Related]
4. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer.
Wang Y; Han C; Teng F; Bai Z; Tian W; Xue F
Int J Gynaecol Obstet; 2017 Jan; 136(1):58-63. PubMed ID: 28099710
[TBL] [Abstract][Full Text] [Related]
6. Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models.
Yang B; Shan B; Xue X; Wang H; Shan W; Ning C; Zhou Q; Chen X; Luo X
PLoS One; 2016; 11(5):e0155145. PubMed ID: 27163153
[TBL] [Abstract][Full Text] [Related]
7. The Utility of Preoperative Serum CA125 Combined with HE4 to Predict Lymph Node Metastasis in Endometrial Cancer.
Prueksaritanond N; Angsathapon S; Insin P
Gynecol Obstet Invest; 2023; 88(1):53-60. PubMed ID: 36596280
[TBL] [Abstract][Full Text] [Related]
8. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.
Angioli R; Plotti F; Capriglione S; Montera R; Damiani P; Ricciardi R; Aloisi A; Luvero D; Cafà EV; Dugo N; Angelucci M; Benedetti-Panici P
Tumour Biol; 2013 Feb; 34(1):571-6. PubMed ID: 23179397
[TBL] [Abstract][Full Text] [Related]
9. Nomogram to Predict Risk of Lymph Node Metastases in Patients With Endometrioid Endometrial Cancer.
Pollom EL; Conklin CM; von Eyben R; Folkins AK; Kidd EA
Int J Gynecol Pathol; 2016 Sep; 35(5):395-401. PubMed ID: 26598977
[TBL] [Abstract][Full Text] [Related]
10. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
[TBL] [Abstract][Full Text] [Related]
11. The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia.
Touhami O; Grégoire J; Renaud MC; Sebastianelli A; Grondin K; Plante M
Gynecol Oncol; 2018 Mar; 148(3):485-490. PubMed ID: 29290489
[TBL] [Abstract][Full Text] [Related]
12. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer.
Chung HH; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Acta Obstet Gynecol Scand; 2006; 85(12):1501-5. PubMed ID: 17260229
[TBL] [Abstract][Full Text] [Related]
13. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
Wang Z; Tao X; Ying C
Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
[TBL] [Abstract][Full Text] [Related]
14. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.
Brennan DJ; Hackethal A; Mann KP; Mutz-Dehbalaie I; Fiegl H; Marth C; Obermair A
BMC Cancer; 2015 Feb; 15():33. PubMed ID: 25655024
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
16. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for pelvic lymph node metastasis in endometrial cancer.
Li Y; Cong P; Wang P; Peng C; Liu M; Sun G
Arch Gynecol Obstet; 2019 Oct; 300(4):1007-1013. PubMed ID: 31435773
[TBL] [Abstract][Full Text] [Related]
18. Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?
Gülseren V; Kocaer M; Özdemir İA; Çakır İ; Sancı M; Güngördük K
Curr Probl Cancer; 2020 Feb; 44(1):100498. PubMed ID: 31395281
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
Feng LY; Liao SB; Li L
J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
[TBL] [Abstract][Full Text] [Related]
20. Value of preoperative neutrophil-lymphocyte ratio and human epididymis protein 4 in predicting lymph node metastasis in endometrial cancer patients.
Gao M; Gao Y
J Obstet Gynaecol Res; 2021 Feb; 47(2):515-520. PubMed ID: 33142358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
